CXCR4 and B-cell chronic lymphocytic leukemia: The decrease in frequencies and expression levels of CXCR4+ and CXCR5+ CLL B cells after CIT may contribute to the increased efficacy of this treatment in reduction of leukemic B cell tumor burden.